Our Company

Our Company

Driven to improve lives.

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.

A message from Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna

Our proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health.

Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in preclinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH. We expect to launch two additional GalXCTM programs in 2016, including one in cardiovascular disease targeting PCSK9 and another in an undisclosed genetic rare disease. We also have the capacity to launch up to three additional programs annually, with the intent to advance five programs into the clinic by the end of 2019.

Our people are our strength.

Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs.

Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.


Dicerna Overview

Founded: 2007
Listed on Nasdaq: 2014
Trading Symbol: DRNA
Number of Employees: 48
Headquarters: Cambridge, Massachusetts